Kewalramani Reshma's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Aug 7, 2025
- Accession no.
- 0000875320-25-000220
- Filed
- Aug 7, 2025
- Trade date
- Aug 6, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $3.90M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kewalramani ReshmaCIK 0001735944 | Director, Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43).
Referenced by the price of 1 transaction in Table I.
- F2
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
- F3
Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53).
Referenced by the price of 1 transaction in Table I.